固定药物喷发二次到埃托里可西布
Nicholas Rawlings1, Sandeep Joshi1, Ann Sandison2
1Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
The British journal of oral & maxillofacial surgery
|May 30, 2024
概括
固定的药物爆发 (FDE) 是延迟的过敏反应,通常会导致皮肤病变. 这项研究详细介绍了一种罕见的FDE病例,该病例仅影响口腔粘膜,并带来了独特的诊断挑战.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 固定的药物喷发 (FDE) 是皮肤药物不良反应,是一种延迟过敏.
- FDE通常表现为反复出现的皮肤病变,通常是红血斑或斑块.
- 在FDE中,口腔粘膜的参与是罕见的,通常呈现出状或状病变.
研究的目的:
- 报告一种仅影响口腔粘膜的固定药物喷发 (FDE) 病例.
- 突出口腔FDE的临床表现和特征.
- 为了解罕见的药物不良反应作出贡献.
主要方法:
- 病例报告详细介绍了一名患有复发性口腔病变的患者.
- 临床检查和药物病史审查.
- 考虑到其他口腔性疾病的差异诊断.
主要成果:
- 患者在口腔粘膜上出现了复发性,明显的红血和侵蚀性病变.
- 在摄入特定药物 (摘要中未指明) 后,病变始终出现.
- 反应仅限于口腔粘膜,没有皮肤表现.
结论:
- 固定的药物喷发可以仅在口腔粘膜上表现出来,挑战典型的呈现.
- 识别口服FDE对于准确诊断和药物不良反应的管理至关重要.
- 需要进一步的研究,以充分阐明口服FDE的机制和临床谱.
相关概念视频
Allergic Drug Reactions
833
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
833
Drug Excretion: Miscellaneous Routes
63
Drug excretion involves various organs, including the liver, intestines, skin, and eyes. In the case of drugs or toxins, they can be actively secreted into bile by transporters in the hepatocyte's canalicular membrane. These substances enter the GI tract during digestion and may be reabsorbed into the body from the intestine. This process, known as enterohepatic recycling, can significantly prolong the presence and effects of a substance in the body. To interrupt this cycle, specific...
63
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Drug Elimination: Non-Renal Routes
2.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.3K
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K


